InterCure Ltd. (INCR)
| Market Cap | 63.54M |
| Revenue (ttm) | 72.42M |
| Net Income (ttm) | -17.43M |
| Shares Out | 45.77M |
| EPS (ttm) | -0.38 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 34,503 |
| Open | 1.360 |
| Previous Close | 1.380 |
| Day's Range | 1.320 - 1.403 |
| 52-Week Range | 1.100 - 3.720 |
| Beta | 0.03 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Dec 3, 2024 |
About INCR
InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in the biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel. [Read more]
News
Are Investors Missing The Forest? 35% Stock Drop Masks The International Potential Of This Weed Company
InterCure Ltd. INCR has shown resilience in its H1 2024 performance despite facing significant challenges, according to equity research by Pablo Zuanic of Zuanic & Associates.
InterCure Announces First Half of 2024 Results: Revenue of NIS 126 million and Adjusted EBITDA of NIS 21 million
NEW YORK and HERZLIYA, Israel, Aug. 29, 2024 (GLOBE NEWSWIRE) -- InterCure Ltd . (NASDAQ: INCR) (TASE: INCR) ("InterCure" or the "Company") is pleased to announce its financial and operating results ...
InterCure Announces Expansion of its Strategic partnership with Cookies to Germany
NEW YORK & HERZLIYA, Israel--(BUSINESS WIRE)--InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company"), the leading vertically integrated medical cannabis company outsid...
InterCure: A Cannabis Industry Leader Still Flying Under The Radar
InterCure is a leading pharmaceutical/medical cannabis company based in Israel and a global leader outside North America. Despite the damage the Hamas attack and the state of war in Israel caused, the...
InterCure to Participate in Canaccord Genuity's 8th Annual Global Cannabis Conference
NEW YORK & HERZLIYA, Israel--(BUSINESS WIRE)--InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc), the leading medical cannabis company outside of North America, today announced that it will part...
InterCure Announces FY2023 Results: Revenue of NIS 356 million and Adjusted EBITDA of NIS 61 million
NEW YORK & HERZLIYA, Israel--(BUSINESS WIRE)--InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) ("InterCure" or the "Company") today announced results for the full year ending December 31, 2023. All amounts ...
InterCure: Bargain Israel Cannabis Play
InterCure Ltd. has faced challenges due to the conflict with Hamas, including not having access to a prime facility in Israel, but is expected to recover. The cannabis market in Israel is still limite...
InterCure Announces Preliminary Estimated 2023 Revenue of NIS 351 million and EBITDA of over NIS 50 million
NEW YORK & HERZLIYA, Israel--(BUSINESS WIRE)---- $INCR #CANNABIS--InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) ("InterCure" or the “Company”) today announced preliminary results for the full year of 202...
InterCure Congratulates Germany on Cannabis Reform, Expanding its Global Footprint
NEW YORK & HERZLIYA, Israel--(BUSINESS WIRE)---- $INCR #CANNABIS--InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company"), the leading medical cannabis company outside ...
PESG Industry Updates: Germany's Cannabis Act and Its Impact on the Medical Cannabis Landscape
LONDON--(BUSINESS WIRE)---- $INCR #CannG--The PESG Research has released an industry update following the regulatory shifts in Germany. Germany is expected to pass the Cannabis Act today (Friday), her...
InterCure Provides an Update Regarding Nir Oz Facility
NEW YORK, and HERZLIYA, Israel, Feb. 13, 2024 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Compan y"), the leading medical cannabis company in Isra...
InterCure Signs Definitive Agreement to Acquire Leon Cannabis Pharmacy Chain
NEW YORK, and HERZLIYA, Israel, Jan. 31, 2024 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Compan y"), the leading medical cannabis company in Isra...
InterCure Wins Cannolam Arbitration Proceeding
NEW YORK and HERZLIYA, Israel , Oct. 31, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Compan y"), the leading medical cannabis company in Isra...
InterCure Provides an Update Regarding the Security Situation in Israel
NEW YORK, and HERZLIYA, Israel, Oct. 17, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Compan y"), the leading medical cannabis company in Isra...
InterCure Announces Record Revenues First Half of 2023 with over 14% growth YOY
Achieved record revenues of NIS 209 million ($ 7 5 million) 1 for the first half of 2023
InterCure: Leader In Israel's Growing Medical Cannabis Market
In mid-August, InterCure, one of the leaders in the global medical cannabis market, will publish financial results for the 2nd quarter of 2023. According to the Ministry of Health, the consumption of ...
InterCure Ltd. Announces Proposed Voluntary Delisting from the Toronto Stock Exchange and shall continue to be listed on the NASDAQ and TASE
NEW YORK and TORONTO and HERZLIYA, Israel, July 10, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc)("InterCure" or the "Compan y"), announced today that...
InterCure Provides an Update About The Lawsuit it Filed Against Cann Pharmaceuticals to Recover Funds Following Failed Merger
NEW YORK and TORONTO and HERZLIYA, Israel, June 09, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc)("InterCure" or the "Compan y"), reports today that, ...
InterCure to Participate in the Cowen 3rd Annual European Cannabis Conference
Mr. Rabinovitch is one of the global cannabis senior executives to participate Mr. Rabinovitch is one of the global cannabis senior executives to participate
InterCure Announces Record Breaking First Quarter Revenues with 22% growth YOY
Achieved record revenues of $40 million for the first quarter Annualized revenue run rate of $159 million Adjusted EBITDA(1) of $6 Million Strong balance sheet with over $45 million cash and Net curre...
InterCure Informs That A Lawsuit Was Filed Against the Company by Minority Shareholders of Its Subsidiary
NEW YORK and TORONTO and HERZLIYA, Israel, April 25, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Compan y"), the leading medica...
InterCure Ltd. Partners with TYSON 2.0 in Israel, Australia, United Kingdom, Germany and Other EU Countries
Leading Global Pharmaceutical Cannabis Company, InterCure, signed an initial collaboration agreement with legendary boxer, entrepreneur and cannabis advocate Mike Tyson's premium cannabis brand Leadin...
InterCure: How Bright Is The Company's Future In 2023
Despite continued market challenges for the cannabis industry, InterCure's revenue continues to grow year-on-year and, more importantly, quarter-on-quarter to NIS 105.6 million in Q4 2022. InterCure's...
InterCure Ltd. (INCR) Q4 2022 Earnings Call Transcript
InterCure Ltd. (NASDAQ:INCR) Q4 2022 Earnings Conference Call April 4, 2023 4:30 PM ET Company Participants Alexander Rabinovitch - CEO & Director Amos Cohen - CFO Conference Call Participants Vivien...
InterCure Reschedules 2022 Full Year Results Conference Call
NEW YORK, TORONTO, and HERZLIYA, Israel, April 03, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd . (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc)("InterCure" or the “Company”) announced today that i...